← All trials
NCT00434811
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2006
- Primary completion
- Sep 1, 2012
- Completion date
- May 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- University of PennsylvaniaStudy chair
- University of MiamiStudy chair
- University of AlbertaStudy chair
- University of California, San FranciscoStudy chair
- Emory UniversityStudy chair
- University of MinnesotaStudy chair
- Northwestern UniversityStudy chair
- Uppsala UniversityStudy chair
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.